Two weeks after being treated with aviptadil, Dr. Jacobo Elgozy recovered from one of the worst COVID-19 cases his doctor had ever seen.
Elgozy, a South Florida doctor, had been taking care of patients for seven months at Mount Sinai Medical Center in Miami Beach before he contracted the virus.
“In a matter of two weeks plus, I recovered like this,” he said as he snapped his fingers, 7News reported. “My lungs started responding like there was no tomorrow. Everybody thinks it was related to the RLF-100 that was given to me, that protected my lungs from any injury or scarring.”
He said that he was already scheduled to undergo a double lung transplant when his doctor thought of aviptadil (previously called RLF-100 but has recently been branded as Zyesami).
“My lungs were white-out, completely gone, non-functional,” he said.
He and his family are thankful for the medical team and the opportunity to have been given access to the drug. Zyesami is still in the clinical trial stage but is made available through an Expanded Access program under FDA guidance.
“When I was able to see them and hug them and know that I was coming home to them, it was heaven,” said Elgozy. “It was very overwhelming. I couldn’t stop crying
Zyesami’s manufacturer, NeuroRx, Inc., released promising preliminary results this week from its Phase 2b/3 trial performed in collaboration with Relief Therapeutics Holdings, AG, in patients with respiratory failure due to critical COVID-19, PR Newswire reported.
